US2018185317A1PendingUtilityA1

Immunotherapeutic agent

55
Assignee: IMMODULON THERAPEUTICS LTDPriority: Dec 29, 2016Filed: Dec 28, 2017Published: Jul 5, 2018
Est. expiryDec 29, 2036(~10.5 yrs left)· nominal 20-yr term from priority
Inventors:Laura Rosa BrunetChristopher A. Lowry
A61K 9/0019A61K 31/231A61P 31/00A61K 31/201
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compounds for use in the treatment of sepsis and/or the prevention or treatment of post-sepsis syndrome.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A pharmaceutical composition comprising a fatty acid of at least C11 comprising a double bond between C10 and C11 and at least one of an adjuvant, a preservative, and a stabiliser. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the fatty acid is from C11 to C24. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the fatty acid comprises only one double bond. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the fatty acid is C16 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the fatty acid is 10(Z)-hexadecenoic acid. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein the fatty acid is an ester of 1,2,3-propanetriol with one or more fatty acids of at least C11, wherein at least one fatty acid has a double bond at the C10-C11 position. 
     
     
         7 . The pharmaceutical composition of  claim 1 , formulated as an injectable liquid. 
     
     
         8 . The pharmaceutical composition of  claim 1 , formulated in a sterile freeze-dried form that is reconstituted prior to use. 
     
     
         9 . The pharmaceutical composition of  claim 1 , formulated as sterile slow-release pellets. 
     
     
         10 . A method of treating sepsis and/or preventing or treating post-sepsis syndrome comprising administration of an effective amount of a fatty acid of at least C11 comprising a double bond between C10 and C11 to a patient in need of such treatment. 
     
     
         11 . The method of  claim 10 , wherein the fatty acid is from C11 to C24. 
     
     
         12 . The method of  claim 10 , wherein the fatty acid comprises only one double bond. 
     
     
         13 . The method of  claim 10 , wherein the fatty acid is C16 
     
     
         14 . The method of  claim 13 , wherein the fatty acid is 10(Z)-hexadecenoic acid. 
     
     
         15 . The method of  claim 10 , wherein the fatty acid is an ester of 1,2,3-propanetriol with one or more fatty acids of at least C11, wherein at least one fatty acid has a double bond at the C10-C11 position. 
     
     
         16 . The method of claim10, further comprising the separate, sequential, or simultaneous administration of an antibacterial, anti-fungal, or anti-viral molecule known to eradicate the infective agent causing sepsis. 
     
     
         17 . The method of  claim 10 , wherein the fatty acid molecule is administered via the parenteral route or the enteral route. 
     
     
         18 . The method of  claim 17 , wherein the parenteral route is selected from subcutaneous, intradermal, subdermal, intraperitoneal, intravenous, and intravesicular injection. 
     
     
         19 . The method of  claim 8 , wherein the fatty acid molecule is administered via intravenous injection. 
     
     
         20 . The method of  claim 10 , wherein the fatty acid molecule is administered via the intratracheal route.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.